Angiogenesis is essential for progression,

invasion and metastasis of SCLC[11]. As a specific target of most tumors VEGF is a target gene of HIF-1 alpha and plays a main role in control of angiogenesis both in physiological and pathological situations, including tumor development and progression. It is mitogenic and angiogenic for endothelial cells, and it can also increase vascular permeability [12]. Identical with previous study [13] our study also found that VEGF-A was upregulated by HIF-1 alpha more than 6-fold in SCLC. But besides VEGF-A, there are several other genes associated with angiogenesis such as PDGFC, PLA2G4A, HMOX1, HMGA2 were upregulated by HIF-1 alpha. These genes were not reported in others literatures and therefore we think the upregulation of these genes may be specific to the angiogenesis Ralimetinib solubility dmso of SCLC when responding to HIF-1 alpha or hypoxia. Some genes had been reported to be found with differential expression in SCLC through microarray analysis. Amplification and overexpression of the MYC family of oncogenes such as MYC (c-Myc), H 89 clinical trial MYCN (N-Myc) and MYCL1 (L-Myc) occured in SCLCs [14] and was common in chemo-refractory disease[15]. In our study not MYC family but SLC family such as SLC6A2 and SLC9A2 were upregulated by HIF-1 alpha. Some genes as TAF5L, TFCP2L4, PHF20, LMO4, TCF20 and RFX2 that were

known to have transcription factor activities express highly in SCLC[16] but the genes that were upregulated by HIF-1 alpha are TRIM22, IRF9, MYOCD, ZNF277 and CREM from our study. Previous study also reported that the high expression of BAI3, D4S234E, DCX, DPYSL5 and GKAP1 which were PLX3397 related

to signal transduction were found in SCLC [16, 17]. In our study signal transduction factor IRS4 and GPER1 were upregulated by HIF-1 alpha more than 6.0-fold. As for IRS4 some researchers Oxymatrine have found that it plays an important role in proliferation/differentiation of tumors and exerts its actions through ERK and p70S6K activation in a ras/raf/MEK1/2 and PI3K/Akt independent manner and in a PKC-dependent way [18]. The GPER1 gene (also known as GPR30) represents an alternative estrogen-responsive receptor, which is highly expressed in tumors where estrogen and progesterone receptors are downregulated and in high-risk tumor patients with lower survival rates[19]. GPER1 is also an important mediator of some single transduction pathways contributing to promote proliferation, metastasis and aggressive behaviors of tumors that are induced by endogenous estrogens, including drugs like hydroxytamoxifen and atrazine or the environmental pollutant cadmium [20–22]. A novel finding different from previous study is that some genes encoding inflammatory response cytokines were upregulated. This maybe provides a broad molecular-biological basis for the inflammatory effect of SCLC.